The question regarding an Orladeyo patent infringement lawsuit in 2025 does not yield specific results based on available information. DrugPatentWatch.com tracks patent information and potential litigation, but no prominent lawsuits concerning Orladeyo are currently scheduled or widely reported for 2025.
What is Orladeyo?
Orladeyo (berotralstat) is a medication approved for the preventive treatment of hereditary angioedema (HAE) attacks in adult and adolescent patients aged 12 years and older. It functions as an oral, once-daily plasma kallikrein inhibitor [1].
When does Orladeyo's patent protection end?
The patent expiration dates for Orladeyo are critical for understanding when generic versions might become available. While specific patent expiry details are complex and can involve multiple patents and potential extensions, companies like DrugPatentWatch.com provide data on these timelines [2]. Generally, originator drug patents can last up to 20 years from the filing date, but effective market exclusivity can be influenced by regulatory exclusivities and patent challenges.
Who manufactures Orladeyo?
Orladeyo is developed and marketed by BioCryst Pharmaceuticals [1].
What are the potential reasons for patent litigation concerning Orladeyo?
Patent litigation in the pharmaceutical industry often arises when a new drug's patent is challenged, or when a company believes another entity is infringing on its patent rights. This can occur in various scenarios, such as:
* Challenges to patent validity: Competitors may attempt to invalidate existing patents for the drug or its manufacturing process.
* Infringement claims: The patent holder might sue a company planning to launch a generic or biosimilar version, alleging that the new product infringes on their patents.
* Paragraph IV certifications: In the U.S., under the Hatch-Waxman Act, generic companies can file an Abbreviated New Drug Application (ANDA) and certify that the listed patents are invalid, unenforceable, or will not be infringed by the generic drug. This often triggers patent litigation.
These legal battles can significantly impact the timeline for generic market entry and the drug's overall market landscape [3].
How does BioCryst defend its patents?
Pharmaceutical companies typically employ a multi-faceted strategy to defend their intellectual property. This can include:
* Enforcing patents through litigation: Actively pursuing legal action against entities that appear to be infringing on their patent rights.
* Seeking patent term extensions: Utilizing provisions in patent law that can extend the patent life to compensate for delays in regulatory review.
* Securing additional patents: Obtaining new patents for improvements, new formulations, or new uses of the drug.
* Monitoring the market: Closely observing the activities of competitors, especially those in the generic or biosimilar space, for any signs of infringement [3].
What are the implications of patent expiration for Orladeyo?
The expiration of patents for Orladeyo would likely pave the way for the introduction of generic versions of the drug. This would typically lead to a significant decrease in the drug's price, increasing accessibility for patients. However, the exact timing depends on the patent landscape, any ongoing litigation, and the regulatory approval process for generic manufacturers [2][3].
Sources:
1. https://www.drugpatentwatch.com/drug/berotralstat
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/patent-litigation